Thelansis

  Acute myeloid leukemia (AML) is characterized by the uncontrolled growth of undifferentiated myeloid stem cells, accumulating immature myeloblasts. The standard approach to induce remission in AML has been a chemotherapy regimen combining cytarabine and anthracycline (commonly called "7+3") for thirty years. However, relapse and refractory disease persist despite its long-standing use, with a median overall survival of under 6 months. Several factors have been linked to worse outcomes, including age exceeding 65 years, unfavorable cytogenetics, and a first complete remission lasting less than 12 months. The treatment of relapsed or refractory AML presents low remission rates following initial salvage therapy, and these rates decline further with subsequent treatment attempts. The sole curative option for relapsed or refractory AML patients is a hematopoietic stem cell transplant, but its high mortality risk renders it unsuitable for many patients. Thelansis’s “Relapsed...